PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Net income growth above 1.5x RVPH's 25.18%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
0.99%
D&A growth of 0.99% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Negative yoy SBC while RVPH is 59.23%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
66.71%
Slight usage while RVPH is negative at -188.51%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
A yoy AP increase while RVPH is negative at -164.57%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-209.52%
Both reduce yoy usage, with RVPH at -226.46%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
100.00%
Well above RVPH's 115.38%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
51.97%
Some CFO growth while RVPH is negative at -114.56%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Negative yoy issuance while RVPH is 344.22%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.